BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35227606)

  • 1. Cost-effectiveness of population-wide genomic screening for Lynch syndrome in the United States.
    Guzauskas GF; Jiang S; Garbett S; Zhou Z; Spencer SJ; Snyder SR; Graves JA; Williams MS; Hao J; Peterson JF; Veenstra DL
    Genet Med; 2022 May; 24(5):1017-1026. PubMed ID: 35227606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
    Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
    JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of genetic diagnostic strategies for Lynch syndrome in Italy.
    Pastorino R; Basile M; Tognetto A; Di Marco M; Grossi A; Lucci-Cordisco E; Scaldaferri F; De Censi A; Federici A; Villari P; Genuardi M; Ricciardi W; Boccia S
    PLoS One; 2020; 15(7):e0235038. PubMed ID: 32609729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population.
    Cenin DR; Naber SK; Lansdorp-Vogelaar I; Jenkins MA; Buchanan DD; Preen DB; Ee HC; O'Leary P
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1737-1744. PubMed ID: 29645364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
    Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
    Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States.
    Spencer SJ; Jones LK; Guzauskas GF; Hao J; Williams MS; Peterson JF; Veenstra DL
    J Clin Lipidol; 2022; 16(5):667-675. PubMed ID: 35961838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Swiss cost-effectiveness analysis of universal screening for Lynch syndrome of patients with colorectal cancer followed by cascade genetic testing of relatives.
    Salikhanov I; Heinimann K; Chappuis P; Buerki N; Graffeo R; Heinzelmann V; Rabaglio M; Taborelli M; Wieser S; Katapodi MC
    J Med Genet; 2022 Sep; 59(9):924-930. PubMed ID: 34782441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome.
    Snowsill T; Huxley N; Hoyle M; Jones-Hughes T; Coelho H; Cooper C; Frayling I; Hyde C
    Health Technol Assess; 2014 Sep; 18(58):1-406. PubMed ID: 25244061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Genomic Screening for Three Common Hereditary Conditions : A Cost-Effectiveness Analysis.
    Guzauskas GF; Garbett S; Zhou Z; Schildcrout JS; Graves JA; Williams MS; Hao J; Jones LK; Spencer SJ; Jiang S; Veenstra DL; Peterson JF
    Ann Intern Med; 2023 May; 176(5):585-595. PubMed ID: 37155986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis.
    Gallego CJ; Shirts BH; Bennette CS; Guzauskas G; Amendola LM; Horike-Pyne M; Hisama FM; Pritchard CC; Grady WM; Burke W; Jarvik GP; Veenstra DL
    J Clin Oncol; 2015 Jun; 33(18):2084-91. PubMed ID: 25940718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age.
    Leenen CH; Goverde A; de Bekker-Grob EW; Wagner A; van Lier MG; Spaander MC; Bruno MJ; Tops CM; van den Ouweland AM; Dubbink HJ; Kuipers EJ; Dinjens WN; van Leerdam ME; Steyerberg EW
    Genet Med; 2016 Oct; 18(10):966-73. PubMed ID: 26938782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome.
    Kang YJ; Killen J; Caruana M; Simms K; Taylor N; Frayling IM; Snowsill T; Huxley N; Coupe VM; Hughes S; Freeman V; Boussioutas A; Trainer AH; Ward RL; Mitchell G; Macrae FA; Canfell K
    Med J Aust; 2020 Feb; 212(2):72-81. PubMed ID: 31595523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan.
    Chen YE; Kao SS; Chung RH
    PLoS One; 2016; 11(8):e0160599. PubMed ID: 27482709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 15. Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective.
    Sie AS; Mensenkamp AR; Adang EMM; Ligtenberg MJL; Hoogerbrugge N
    Ann Oncol; 2014 Oct; 25(10):2001-2007. PubMed ID: 25081898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting.
    Snowsill TM; Ryan NAJ; Crosbie EJ; Frayling IM; Evans DG; Hyde CJ
    PLoS One; 2019; 14(8):e0221419. PubMed ID: 31469860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which Lynch syndrome screening programs could be implemented in the "real world"? A systematic review of economic evaluations.
    Di Marco M; DAndrea E; Panic N; Baccolini V; Migliara G; Marzuillo C; De Vito C; Pastorino R; Boccia S; Villari P
    Genet Med; 2018 Oct; 20(10):1131-1144. PubMed ID: 29300371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of patient preferences on the cost-effectiveness of screening for Lynch syndrome.
    Wang G; Kuppermann M; Kim B; Phillips KA; Ladabaum U
    Am J Manag Care; 2012 May; 18(5):e179-85. PubMed ID: 22694112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of screening strategies for Lynch syndrome.
    Barzi A; Sadeghi S; Kattan MW; Meropol NJ
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25794514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined population genomic screening for three high-risk conditions in Australia: a modelling study.
    Lacaze P; Marquina C; Tiller J; Brotchie A; Kang YJ; Merritt MA; Green RC; Watts GF; Nowak KJ; Manchanda R; Canfell K; James P; Winship I; McNeil JJ; Ademi Z
    EClinicalMedicine; 2023 Dec; 66():102297. PubMed ID: 38192593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.